ArticleInternational journal of clinical and experimental pathology2015
MiR-145 suppressed human retinoblastoma cell proliferation and invasion by targeting ADAM19.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- ADAM19: biological characteristics and implications in disease pathology and clinical applications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Review
- IER3: exploring its dual function as an oncogene and tumor suppressor.Cancer gene therapy · 2025Article
- ADAM10 and ADAM17-Novel Players in Retinoblastoma Carcinogenesis.International journal of molecular sciences · 2022Article
- Role of non-coding RNAs and exosomal non-coding RNAs in retinoblastoma progression.Frontiers in cell and developmental biology · 2022Review
- Circular RNA has_circ_0000034 accelerates retinoblastoma advancement through the miR-361-3p/ADAM19 axis.Molecular and cellular biochemistry · 2021Article
- A Novel Circular RNA circCSPP1 Promotes Liver Cancer Progression by Sponging miR-1182.OncoTargets and therapy · 2021Article
- Long non-coding RNA CASC9 promotes the progression of retinoblastoma via interacting with miR-145-5p.Cell cycle (Georgetown, Tex.) · 2020Article
- Transcriptome network of the papillary thyroid carcinoma radiation marker CLIP2.Radiation oncology (London, England) · 2020Article
- Long noncoding RNA NORAD regulates lung cancer cell proliferation, apoptosis, migration, and invasion by the miR-30a-5p/ADAM19 axis.International journal of clinical and experimental pathology · 2020Article
- Diagnostic value of miR-145 and its regulatory role in macrophage immune response in tuberculosis.Genetics and molecular biology · 2020Article
- Biomarkers in retinoblastoma.International journal of ophthalmology · 2020Review
- MicroRNA‑98 suppresses cell growth and invasion of retinoblastoma via targeting the IGF1R/k‑Ras/Raf/MEK/ERK signaling pathway.International journal of oncology · 2019Article
- MicroRNA-98 targets HMGA2 to inhibit the development of retinoblastoma through mediating Wnt/β-catenin pathway.Cancer biomarkers : section A of Disease markers · 2019Article
- MiR-145: a potential biomarker of cancer migration and invasion.American journal of translational research · 2019Review
- Expression profiles and prognostic value of miRNAs in retinoblastoma.Journal of cancer research and clinical oncology · 2019Review
- Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma.Scientific reports · 2017Article
- miR-223 decreases cell proliferation and enhances cell apoptosis in acute myeloid leukemia via targeting FBXW7.Oncology letters · 2016Article
- miR-145 Contributes to the Progression of Cervical Carcinoma by Directly Regulating FSCN1.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) play critical roles in retinoblastoma (RB) initiation and progression, aberrant expression of miR-145 had been frequently reported in cancer studies. However, the role and mechanism of its function in RB is still unclear. In this study, our data showed that miR-145 was downregulated in RB tissues and cell lines. Overexpression of miR-145 suppressed RB cell proliferation, migration and invasion in vitro. ADAM19 was identified as a direct target of miR-145. Silencing of ADAM19 significantly inhibited RB cell proliferation, migration and invasion. In addition, a reverse correlation between miR-145 and ADAM19 expression was noted in RB tissues. Taken together, these findings suggested that miR-145 functions as a tumor suppressor in RB by directly targeting ADAM19. miR-145 could be an anticancer therapeutic target for RB patients.
Indexed as
Identifiers
26823772PMC4713558W2412201863What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.